GILD - Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts
2024-04-22 14:20:23 ET
Summary
- Hookipa Pharma is conducting a call on 04/25/24 to share lead asset HB-200's pivotal trial design. A Phase 2a clinical update is due in 2Q'24.
- The company's shares closed at $0.733, with a valuation of approximately $72.53. Positive data could push shares up 3-5x while negative news could cut the stock in half or worse.
- Hookipa's partnership with Gilead provides financial support for its lead asset allowing the company to focus on its pivotal-ready program.
On Friday April 19 th , shares of Hookipa Pharma ( HOOK ) closed at $0.733/s with a valuation ~$72.53M. To be clear, this company is a High Risk/High Reward play and as such, is probably not a suitable investment for most investor’s portfolios. Typically, I would build a 2% position at most in my portfolio for this type of early clinical development target when I am interested. However, in this particular situation, I have increased my exposure through an additional 1% in physical shares and another 1% through an assortment of options for ~4% exposure. Here is why:
1) On 04/25/24, HOOK will share its pivotal Ph2/3 design for lead asset HB-200. This implies they are still on-track to start their registrational trial in mid’24....
Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts